Clinical Trial

Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

Name: Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG — clinical trial record (NCT07644312)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.

Trial Details

NCT Number	NCT07644312
Lead Sponsor	Nationwide Children's Hospital
Conditions	High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Replication Repair Deficient
Enrollment	12 participants
Start Date	2027-03-01
Primary Completion	2033-03-01 (estimated)
Study Completion	2038-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-12